GO:2001015 negative regulation of skeletal muscle cell differentiation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001015 describes any biological process that reduces the frequency, rate or extent of skeletal muscle cell differentiation, a key step in muscle development and regeneration.
• Negative regulators of skeletal muscle differentiation include secreted factors such as myostatin (MSTN) and Ccl8, and intracellular proteins like AEBP1 and cell-cycle inhibitors.
• The Hippo-YAP/TAZ signaling pathway is a major negative regulator of skeletal muscle differentiation and is implicated in musculoskeletal disorders.
• Cell cycle regulators, including cyclins and CDK inhibitors, control the balance between skeletal muscle stem cell quiescence, activation, and differentiation.
• Mitochondrial transcription factor A (Tfam) expression is regulated during skeletal muscle differentiation, linking mitochondrial biogenesis to this process.
• Nutritional and metabolic factors, such as betaine, can influence skeletal muscle fiber-type composition through NFATc1/MyoD signaling.
Description
Skeletal muscle cell differentiation is the process by which myoblasts exit the cell cycle, fuse into multinucleated myotubes, and express contractile proteins. This process is essential for muscle development, growth, and regeneration after injury. GO:2001015, negative regulation of skeletal muscle cell differentiation, encompasses all molecular events that inhibit or delay this differentiation program. Understanding these negative regulators is critical because their dysregulation contributes to muscle wasting, impaired regeneration, and musculoskeletal disorders. Recent studies have identified diverse negative regulators, including secreted factors like myostatin (MSTN) and Ccl8, and intracellular proteins such as AEBP1. These factors act through signaling pathways that converge on myogenic regulatory factors (MRFs) like MyoD, ultimately controlling the timing and extent of differentiation. This article synthesizes current knowledge on GO:2001015, covering its definition, mechanisms, key genes, disease relevance, and experimental approaches for research.
negative regulation of skeletal muscle cell differentiation At A Glance
| GO ID | GO:2001015 |
|---|---|
| GO term | negative regulation of skeletal muscle cell differentiation |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Inhibition or delay of skeletal muscle cell differentiation |
| Related processes | Muscle regeneration, cell cycle regulation, Hippo signaling |
| Key regulators | MSTN, Ccl8, AEBP1, CDK inhibitors, YAP/TAZ |
| Disease relevance | Muscle wasting, musculoskeletal disorders, cancer cachexia |
What Is GO:2001015?
GO:2001015 is defined as any process that stops, prevents, or reduces the frequency, rate or extent of skeletal muscle cell differentiation. Skeletal muscle cell differentiation is the process in which a relatively unspecialized cell acquires specialized features of a skeletal muscle cell, typically involving myoblast fusion and expression of muscle-specific genes. Negative regulation of this process can occur at multiple levels, including inhibition of myogenic transcription factors, blockade of cell cycle exit, or activation of signaling pathways that suppress differentiation.
Why Is negative regulation of skeletal muscle cell differentiation Important in Cell Biology?
Negative regulation of skeletal muscle cell differentiation is crucial for proper muscle development and regeneration. It prevents premature differentiation of muscle stem cells, maintains the quiescent satellite cell pool, and ensures that differentiation occurs only under appropriate conditions. Dysregulation of this process is linked to impaired muscle regeneration, muscle atrophy, and diseases such as musculoskeletal disorders and cancer cachexia. Understanding the negative regulators provides potential therapeutic targets for enhancing muscle repair and treating muscle-related diseases.
• Maintains muscle stem cell quiescence and prevents premature differentiation.
• Controls the timing of muscle regeneration after injury.
• Dysregulation leads to impaired muscle repair and muscle wasting.
• Involved in musculoskeletal disorders such as muscular dystrophies and sarcopenia.
• Negatively regulates differentiation in non-muscle contexts, e.g., oral squamous cell carcinoma.
• Provides targets for therapeutic intervention in muscle degenerative diseases.
• Links cell cycle regulation to differentiation decisions.
• Integrates metabolic and nutritional signals, such as betaine, into muscle fiber-type specification.
• Modulates mitochondrial function through Tfam during differentiation.
• Impacts bovine muscle development, relevant for agriculture.
What Happens During negative regulation of skeletal muscle cell differentiation?
Inhibition of Myogenic Transcription Factors
In simple terms: Proteins that block the master switches of muscle differentiation.
MyoD and other myogenic regulatory factors (MRFs) are essential for skeletal muscle differentiation. Negative regulators can inhibit their activity or expression. For example, NFATc1 signaling can interfere with MyoD-dependent transcription, as shown in studies on betaine affecting muscle fiber-type composition. Additionally, AEBP1 acts as a negative regulator of skeletal muscle cell differentiation in oral squamous cell carcinoma, potentially by modulating transcription factor networks.
Activation of Signaling Pathways that Suppress Differentiation
In simple terms: External signals that tell muscle cells not to differentiate.
The Hippo-YAP/TAZ signaling pathway is a key negative regulator of skeletal muscle differentiation. When activated, it promotes YAP/TAZ nuclear localization, which inhibits myogenic differentiation and contributes to musculoskeletal disorders. Myostatin (MSTN), a member of the TGF-beta superfamily, is a well-known negative regulator of muscle growth and differentiation. MSTN signaling activates SMAD2/3, which suppresses MyoD activity and inhibits differentiation. In bovine satellite cells, MSTN regulates differentiation via PSMA6-mediated AKT signaling.
Cell Cycle Regulation and Quiescence Maintenance
In simple terms: Keeping muscle stem cells in a dormant state to prevent differentiation.
Skeletal muscle stem cells (satellite cells) must remain quiescent until needed. Cell cycle inhibitors, such as CDK inhibitors (CDKIs), play a critical role in maintaining quiescence and preventing premature differentiation. The balance between cyclins and CDKIs controls the transition from quiescence to activation and differentiation. Negative regulation of differentiation often involves upregulation of CDKIs like p21 and p27, which block cell cycle progression and promote differentiation, but in some contexts, they maintain quiescence.
Secreted Factors and Inflammatory Mediators
In simple terms: Molecules released by cells that inhibit muscle differentiation.
Muscle cell-derived Ccl8 is a negative regulator of skeletal muscle regeneration. It acts by recruiting inflammatory cells or directly inhibiting myoblast differentiation. Other secreted factors, such as myostatin, circulate and inhibit muscle growth in an endocrine manner. These factors provide systemic control over muscle differentiation.
Mitochondrial and Metabolic Regulation
In simple terms: How energy metabolism influences the decision to differentiate.
Mitochondrial transcription factor A (Tfam) expression is regulated during skeletal muscle cell differentiation, and its levels affect mitochondrial biogenesis. Negative regulation of differentiation can involve suppression of Tfam and mitochondrial function, which are required for the metabolic demands of differentiation. Nutritional factors like betaine can modulate this process by affecting NFATc1/MyoD signaling.
Key Genes Involved in GO:2001015 negative regulation of skeletal muscle cell differentiation
The following genes and proteins have been experimentally implicated in the negative regulation of skeletal muscle cell differentiation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGF-beta family member that inhibits muscle growth and differentiation | Therapeutic target for muscle wasting; studied in bovine and human models |
| CCL8 | Muscle cell-derived chemokine that negatively regulates regeneration | Potential target to enhance muscle repair |
| AEBP1 | Transcriptional repressor that inhibits skeletal muscle differentiation | Implicated in oral squamous cell carcinoma; potential oncogenic role |
| YAP1 | Hippo pathway effector that inhibits myogenic differentiation | Key node in musculoskeletal disorders; target for regeneration |
| WWTR1 (TAZ) | Hippo pathway effector that inhibits myogenic differentiation | Similar to YAP1; regulates differentiation in musculoskeletal tissues |
| CDKN1A (p21) | CDK inhibitor that can block cell cycle and affect differentiation | Regulates quiescence and differentiation decisions |
| CDKN1B (p27) | CDK inhibitor involved in quiescence maintenance | Controls satellite cell activation |
| TFAM | Mitochondrial transcription factor; its expression is regulated during differentiation | Links mitochondrial biogenesis to differentiation |
| NFATC1 | Transcription factor that can interfere with MyoD activity | Mediates effects of betaine on fiber-type composition |
| MYOD1 | Master myogenic transcription factor; often inhibited by negative regulators | Central target of negative regulation |
| PSMA6 | Proteasome subunit involved in MSTN-mediated AKT signaling | Mediates MSTN effects on bovine satellite cells |
| AKT1 | Kinase that promotes differentiation; inhibited by MSTN signaling | Integration point for growth factor signaling |
| SMAD2/3 | Transcription factors downstream of MSTN that inhibit myogenesis | Mediators of TGF-beta family signaling |
| CCND1 | Cyclin D1; promotes cell cycle progression and can delay differentiation | Balances proliferation and differentiation |
| CDK4 | Cyclin-dependent kinase that partners with cyclin D | Cell cycle regulator in muscle stem cells |
| CDK6 | Cyclin-dependent kinase that partners with cyclin D | Cell cycle regulator in muscle stem cells |
| MEF2C | Myogenic transcription factor; can be inhibited by negative regulators | Cooperates with MyoD; target of repression |
How Is negative regulation of skeletal muscle cell differentiation Regulated?
The negative regulation of skeletal muscle cell differentiation is itself tightly regulated by multiple signaling pathways. The Hippo-YAP/TAZ pathway is a central regulator; when active, it inhibits differentiation, and its dysregulation is linked to musculoskeletal disorders. Myostatin signaling through SMAD2/3 provides another layer of negative control, and its inhibition can promote muscle growth. Cell cycle regulators, including cyclins and CDK inhibitors, integrate extracellular signals to decide between quiescence, proliferation, and differentiation. Metabolic factors such as betaine can modulate this process by affecting NFATc1/MyoD signaling. Additionally, mitochondrial function, regulated by Tfam, influences the capacity of cells to differentiate.
negative regulation of skeletal muscle cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Muscle atrophy, cachexia | MSTN knockout mice; overexpression in C2C12 cells |
| CCL8 | Impaired muscle regeneration, inflammatory myopathies | Ccl8 knockout mice; muscle injury models |
| AEBP1 | Oral squamous cell carcinoma, cancer cachexia | AEBP1 knockdown in OSCC cell lines; xenograft models |
| YAP1 | Musculoskeletal disorders, muscular dystrophy | YAP1 conditional knockout mice; muscle injury |
| TFAM | Mitochondrial myopathies | Tfam knockout in muscle cells; mitochondrial function assays |
Muscle Wasting and Musculoskeletal Disorders
Dysregulation of negative regulators of skeletal muscle differentiation contributes to muscle wasting conditions. For example, overactivation of the Hippo-YAP/TAZ pathway is implicated in musculoskeletal disorders, including muscular dystrophies and sarcopenia. Myostatin, a potent negative regulator, is elevated in conditions of muscle atrophy and cachexia, and its inhibition is a therapeutic strategy. Ccl8, a negative regulator of regeneration, may exacerbate muscle damage in inflammatory myopathies.
Cancer and Cachexia
AEBP1 acts as a negative regulator of skeletal muscle cell differentiation in oral squamous cell carcinoma, suggesting a role in cancer-associated muscle wasting. Cancer cachexia involves systemic inflammation and muscle loss, where factors like myostatin and Ccl8 may play a role. Targeting these negative regulators could ameliorate cancer-induced muscle wasting.
Metabolic and Mitochondrial Myopathies
Mitochondrial dysfunction is a hallmark of various myopathies. Tfam, a key regulator of mitochondrial transcription, is regulated during skeletal muscle differentiation, and its dysregulation may contribute to mitochondrial myopathies. Nutritional factors like betaine influence muscle fiber-type composition, which has implications for metabolic health.
From negative regulation of skeletal muscle cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate skeletal muscle differentiation? | CRISPR knockout of gene X in C2C12 myoblasts, followed by differentiation assays |
| Does a point mutation in gene X affect its function in differentiation? | CRISPR point mutation knock-in in C2C12 or primary myoblasts |
| How does a tagged version of protein X behave during differentiation? | CRISPR knock-in of fluorescent or epitope tag at endogenous locus |
| Does overexpression of gene X inhibit differentiation? | Lentiviral overexpression in C2C12 cells, followed by myotube formation assays |
| What is the role of gene X in muscle regeneration in vivo? | Conditional knockout or overexpression in mouse satellite cells |
| Can CRISPR activation of gene X enhance differentiation? | CRISPRa in primary myoblasts or in vivo |
How to Study the negative regulation of skeletal muscle cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways affected by negative regulators |
| Proteomics | Protein abundance and modifications | Map signaling networks |
| Immunofluorescence | Myotube formation and fusion index | Quantify differentiation inhibition |
| CRISPR knockout screen | Loss-of-function effects on differentiation | Discover novel negative regulators |
| CRISPR activation screen | Gain-of-function effects on differentiation | Identify suppressors of differentiation |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
| qRT-PCR | mRNA levels of myogenic markers | Assess differentiation status |
| Mitochondrial function assays | Oxygen consumption, membrane potential | Link metabolism to differentiation |
Transcriptomic Analysis (RNA-seq)
RNA sequencing can identify global changes in gene expression during skeletal muscle differentiation and upon perturbation of negative regulators. For example, RNA-seq of C2C12 cells overexpressing AEBP1 revealed downregulation of myogenic genes. This method helps uncover pathways affected by negative regulators.
Proteomic and Phosphoproteomic Profiling
Mass spectrometry-based proteomics can quantify protein abundance and post-translational modifications during differentiation. Studies on MSTN signaling have used phosphoproteomics to identify AKT substrates. This approach reveals signaling networks controlled by negative regulators.
Imaging and Fusion Assays
Immunofluorescence for myosin heavy chain (MyHC) and nuclei staining allows quantification of myotube formation and fusion index. This is a standard method to assess differentiation and its inhibition. Live-cell imaging can track fusion dynamics.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of skeletal muscle differentiation. Such screens in C2C12 cells or primary myoblasts can uncover genes like AEBP1 or Ccl8. These unbiased approaches are powerful for discovery.
How CRISPR Can Be Used to Study GO:2001015 negative regulation of skeletal muscle cell differentiation
Knockout
CRISPR knockout of candidate negative regulators can be used to test whether their loss enhances skeletal muscle differentiation. For example, knocking out AEBP1 in oral squamous cell carcinoma cells or Ccl8 in muscle cells can increase differentiation markers. This approach is straightforward and effective for loss-of-function studies.
Point Mutation
Point mutations can be introduced to model disease-associated variants or to abrogate specific post-translational modification sites. For instance, mutating phosphorylation sites in YAP1 or SMAD2/3 can reveal their role in differentiation. This requires homology-directed repair (HDR) with a donor template.
Knock-in
Knock-in of tags (e.g., GFP, FLAG) or reporter genes allows visualization and tracking of endogenous proteins. Tagging MyoD or MEF2C can help study their dynamics during differentiation. Knock-in of lineage tracers can also track cell fate.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high expression of negative regulators to assess their inhibitory effects. Overexpressing MSTN or AEBP1 in myoblasts inhibits differentiation, confirming their function. This is useful for gain-of-function studies.
How EDITGENE Supports negative regulation of skeletal muscle cell differentiation Research
Researchers studying negative regulation of skeletal muscle cell differentiation-related genes often need to determine whether a candidate gene is causally involved in inhibiting or delaying differentiation. This requires precise genetic manipulation, such as knockout, point mutation, knock-in, or overexpression, followed by functional assays. EDITGENE provides comprehensive CRISPR-based services to accelerate such research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of skeletal muscle cell differentiation research.
Frequently Asked Questions About negative regulation of skeletal muscle cell differentiation
What is GO:2001015?
GO:2001015 is a Gene Ontology term for any biological process that negatively regulates skeletal muscle cell differentiation, meaning it reduces the frequency, rate, or extent of this differentiation process.
What genes are involved in negative regulation of skeletal muscle cell differentiation?
Key genes include MSTN, CCL8, AEBP1, YAP1, WWTR1 (TAZ), CDKN1A, CDKN1B, and TFAM, among others.
How does myostatin inhibit muscle differentiation?
Myostatin (MSTN) activates SMAD2/3 signaling, which suppresses MyoD activity and inhibits myoblast differentiation.
What is the role of Hippo signaling in muscle differentiation?
The Hippo-YAP/TAZ pathway negatively regulates skeletal muscle differentiation; when active, YAP/TAZ inhibit myogenic differentiation and contribute to musculoskeletal disorders.
Can CRISPR be used to study negative regulators of muscle differentiation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to study gene function in skeletal muscle differentiation.
What diseases are associated with dysregulated negative regulation of muscle differentiation?
Muscle wasting, musculoskeletal disorders, cancer cachexia, and mitochondrial myopathies are linked to dysregulation of these processes.
How is Tfam involved in skeletal muscle differentiation?
Tfam expression is regulated during differentiation, and it controls mitochondrial biogenesis, which is required for the metabolic demands of differentiation.
What is the role of Ccl8 in muscle regeneration?
Ccl8 is a muscle cell-derived chemokine that acts as a negative regulator of skeletal muscle regeneration, potentially by modulating inflammation.
How does betaine affect muscle fiber-type composition?
Betaine influences muscle fiber-type composition through NFATc1/MyoD signaling, thereby affecting differentiation and fiber specification.
What experimental models are used to study negative regulation of muscle differentiation?
Common models include C2C12 myoblasts, primary satellite cells, and mouse models with conditional knockouts or overexpression of candidate genes.
Conclusion
GO:2001015, negative regulation of skeletal muscle cell differentiation, is a critical biological process that controls muscle development, regeneration, and homeostasis. Dysregulation of this process contributes to a range of diseases, including muscle wasting, musculoskeletal disorders, and cancer cachexia. Key negative regulators such as myostatin, Ccl8, AEBP1, and Hippo pathway components offer promising therapeutic targets. Advances in CRISPR-based gene editing and functional genomics are accelerating the discovery of new regulators and their mechanisms. EDITGENE provides comprehensive services to support research in this field, from knockout and knock-in models to CRISPR screens and bioinformatics.
References
- 1. Han J et al.. 2024. Emerging role and function of Hippo-YAP/TAZ signaling pathway in musculoskeletal disorders.. Stem Cell Res Ther 15(1):386 PMID: 39468616
- 2. Boss-Kennedy A et al.. 2024. Muscle cell-derived Ccl8 is a negative regulator of skeletal muscle regeneration.. FASEB J 38(14):e23841 PMID: 39051762
- 3. Okazaki F et al.. 2024. AEBP1 is a negative regulator of skeletal muscle cell differentiation in oral squamous cell carcinoma.. Sci Rep 14(1):27425 PMID: 39521917
- 4. Sharma M et al.. 2015. Myostatin: expanding horizons.. IUBMB Life 67(8):589-600 PMID: 26305594
- 5. Ma T et al.. 2025. MSTN Regulates Bovine Skeletal Muscle Satellite Cell Differentiation via PSMA6-Mediated AKT Signaling Pathway.. Int J Mol Sci 26(11) PMID: 40507774
- 6. Mademtzoglou D et al.. 2022. From cyclins to CDKIs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation.. Exp Cell Res 420(1):113275 PMID: 35931143
- 7. Collu-Marchese M et al.. 2015. The regulation of mitochondrial transcription factor A (Tfam) expression during skeletal muscle cell differentiation.. Biosci Rep 35(3) PMID: 26182383
- 8. Du J et al.. 2018. The regulation of skeletal muscle fiber-type composition by betaine is associated with NFATc1/MyoD.. J Mol Med (Berl) 96(7):685-700 PMID: 29876588
